Tensions Remain Over tPA for Stroke

Publisher Website
Google Scholar
Abstract
Phoenix—When approved for use in the United States in 1996, tissue-type plasminogen activator (tPA) was hailed by many as a revolutionary breakthrough for the treatment of ischemic stroke. But now, almost seven years later, the use of this thrombolytic agent is at the center of an ongoing debate between proponents who say tPA use remains frustratingly low and the emergency physicians who are faced with treatment decisions in real-world settings.

This publication has 0 references indexed in Scilit: